The following video Q&A; captures interviews we conducted with several physicians who are investigators in Opexa’s Tovaxin clinical trials to share their thoughts about multiple sclerosis, the current treatment landscape and Tovaxin, our T-cell therapy in clinical development. The biographies of the participants are included below.

Click on a question to watch a short video of the clinical investigators’ responses.

Tovaxin Q & A
Please click the questions to watch the video responses.

The statements made by the physicians in this video, including any statements regarding various drugs and treatments, are their personal opinions and observations and are not the opinions or statements of their respective institutions or of Opexa Therapeutics, Inc. Further, the statements in the video should not be considered medical advice and you should consult your own physician regarding any personal medical problems.

The information discussed related to our product candidate is preliminary and investigative. Such product candidate is not approved by the U.S. Food and Drug Administration (FDA), and no conclusions can or should be drawn regarding the safety or effectiveness of the product candidate(s). Only the FDA can determine whether the product candidate is safe and effective for the use(s) being investigated.

Opexa Therapeutics, Inc. has filed a registration statement (including a prospectus) with the SEC for the offering to which this communication relates. Before you invest, you should read the prospectus in that registration statement and other documents the issuer has filed with the SEC for more complete information about the issuer and this offering. You may get these documents for free by visiting EDGAR on the SEC Web site at Alternatively, Opexa Therapeutics, Inc., any underwriter or any dealer participating in the offering will arrange to send you the prospectus if you request it by calling 281-272-9331 or by e-mailing

The following video contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended and Section 21E of the Securities Exchange Act of 1934, as amended. These statements can be identified by the use of forward-looking terminology, including "may," "believe," "will," "expect," "anticipate," "estimate," "plan," "intend," and "forecast," or other similar words. Statements contained in this video are based upon information presently available and assumptions believed to be reasonable. We are not assuming any duty to update this information should those facts change or should we no longer believe the assumptions to be reasonable. Investors are cautioned that all such statements involve risks and uncertainties, including without limitation, statements concerning the causes of diseases, the effects of various treatments, the timing and outcomes of clinical trials and anticipated scientific developments. Actual facts and results may differ materially. Important factors that may cause actual results to differ include, but are not limited to: new scientific understandings of diseases, the actual effects of treatments as determined by valid clinical trials and changes in regulatory requirements. For a detailed discussion of these and other cautionary statements, please refer to the Company’s most recent filings with the SEC, including its Form 10-KSB for the fiscal year ended December 31, 2006.

Physician Bios
Edward J. Fox, M.D., Ph.D.
Brian D. Loftus, M.D.
Clyde E. Markowitz, M.D.